Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenn W Sellers

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|July 19, 2025
A 7-Year Analysis of the U.S. FDA Good Clinical Practice Inspection Outcomes for Marketing ApplicationsCourtney McGuire, Jenn W Sellers, Laurie Muldowney
Therapeutic Innovation & Regulatory Science|March 10, 2026
Lessons and Insights from a Case Study on Clinical Trial FraudCourtney McGuire, Jenn W Sellers, Cheryl Grandinetti, et al.
Therapeutic Innovation & Regulatory Science|May 31, 2022
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|June 6, 2022
Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 24, 2022
Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
The Journal of Clinical Psychiatry|January 7, 2015
The US Food and Drug Administration's perspective on the new antidepressant vortioxetineJing Zhang, Mitchell V Mathis, Jenn W Sellers, et al.
Therapeutic Innovation & Regulatory Science|August 16, 2022
Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines AgencyKassa Ayalew, Yang-Min Ning, Michelle J Foringer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|July 19, 2025
A 7-Year Analysis of the U.S. FDA Good Clinical Practice Inspection Outcomes for Marketing ApplicationsCourtney McGuire, Jenn W Sellers, Laurie Muldowney
Therapeutic Innovation & Regulatory Science|March 10, 2026
Lessons and Insights from a Case Study on Clinical Trial FraudCourtney McGuire, Jenn W Sellers, Cheryl Grandinetti, et al.
Therapeutic Innovation & Regulatory Science|May 31, 2022
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|June 6, 2022
Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 24, 2022
Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
The Journal of Clinical Psychiatry|January 7, 2015
The US Food and Drug Administration's perspective on the new antidepressant vortioxetineJing Zhang, Mitchell V Mathis, Jenn W Sellers, et al.
Therapeutic Innovation & Regulatory Science|August 16, 2022
Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines AgencyKassa Ayalew, Yang-Min Ning, Michelle J Foringer, et al.
Pageof 1